Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Sign in
Subscribe
Clinical Topics
View All
Addiction
ADHD
Alzheimer’s Disease
Anxiety
Bipolar Disorder
Depression
Movement Disorders
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia/Schizoaffective Disorders
Sleep
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
UZEDY: Information from Industry
View All
John M. Davis, MD
JCP
Original Research
Relapse of Aggressive and Disruptive Behavior in Mentally Retarded Adults Following Antipsychotic Drug Withdrawal Predicts Psychotropic Drug Use a Decade Later
August 15, 2006
John M. Davis
,
L. Jarrett Barnhill
,
David S. Janowsky
, et al
JCP
Article
Choice of Maintenance Medication for Schizophrenia
November 1, 2003
John M. Davis
,
Nancy Chen
JCP
Original Research
Olanzapine for Self-Injurious, Aggressive, and Disruptive Behaviors in Intellectually Disabled Adults: A Retrospective, Open-Label, Naturalistic Trial
October 15, 2003
John M. Davis
,
L. Jarrett Barnhill
,
David S. Janowsky
JCP
Original Research
The Effects of Olanzapine on the 5 Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American and International Trials
October 1, 2001
John M. Davis
,
Nancy Chen
JCP
Original Research
The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American Trials
December 15, 1997
Stephen R. Marder
,
John M. Davis
,
Guy Chouinard
«
1
2